{"id":"W4413871179","doi":"10.1016/j.jaad.2025.05.1113","title":"59674 Randomized Phase 3 trial of spesolimab in patients with ulcerative pyoderma gangrenosum: A study protocol","year":2025,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Autoimmune and Inflammatory Disorders","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Medicine; Pyoderma gangrenosum; Dermatology; Randomized controlled trial; Protocol (science); Surgery; Internal medicine; Pathology; Disease; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003038531,0.003097928,0.003744417,0.0007571013,0.001041603,0.001573283,0.001413753,0.002917032,0.03867991],"category_scores_gemma":[0.002497443,0.001277915,0.002693522,0.0006804448,0.001406456,0.001005407,0.0008372451,0.004320811,0.005714441],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001408734,"about_ca_system_score_gemma":0.003997042,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001531714,"about_ca_topic_score_gemma":0.004216258,"domain_scores_codex":[0.9985551,0.0007486484,0.0001004595,0.000193021,0.0001154565,0.0002872156],"domain_scores_gemma":[0.9990465,0.0002329285,0.0002018716,0.0000937787,0.0000925136,0.0003323707],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9735644,0.002909059,0.0003068369,0.001448012,0.0008975752,0.00007119944,0.00004126811,0.0004583824,0.001479161,0.0004239679,0.006337862,0.01206216],"study_design_scores_gemma":[0.9910289,0.006105487,0.0004151034,0.00004984897,0.0002057501,0.00001282288,0.000005974143,0.0001216032,0.00007751917,0.0001545678,0.001813938,0.000008439632],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.3577312,0.01227566,0.01030151,0.006313439,0.004516896,0.5386667,0.03086972,0.001846721,0.03747825],"genre_scores_gemma":[0.4171808,0.00561798,0.01361754,0.01139905,0.001451598,0.5087822,0.01127779,0.0002101076,0.03046288],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.03867991,"threshold_uncertainty_score":0.1293972,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009000177000796068,"score_gpt":0.3464731479822631,"score_spread":0.337472970981467,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}